EGFR and non-small cell lung carcinoma: However, the T790M mutation (threonine to methionine) within the ATP site of the EGFR frequently occurs in NSCLC patients (about 60%), and these patients develop resistance to drugs that target EGFR, which leads to the failure of EGFR-targeted therapy [98,99].